nach oben

Diabetologia

Erschienen in:

01.04.2004 | Article

Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy

verfasst von: F. Li, C. Szabó, P. Pacher, G. J. Southan, O. I. Abatan, T. Charniauskaya, M. J. Stevens, I. G. Obrosova

Erschienen in: Diabetologia | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis.

Poly(ADP-ribose) polymerase activation depletes NAD⁺ and high-energy phosphates, activates protein kinase C, and affects gene expression in various tissues. This study was designed to characterise the effects of the potent, orally active poly(ADP-ribose) polymerase inhibitor PJ34 in the Wistar rat model of early diabetic neuropathy.

Methods.

Control and streptozotocin-diabetic rats were maintained with or without PJ34 treatment (30 mg·kg⁻¹·day⁻¹) for two weeks, after two weeks without treatment. Endoneurial blood flow was assessed by hydrogen clearance; metabolites and high-energy phosphates were assayed by enzymatic spectrofluorometric methods; and poly(ADP-ribose) was detected by immunohistochemistry.

Results.

Blood glucose concentrations were increased to a similar extent in untreated and PJ34-treated diabetic rats compared with controls. Intense poly(ADP-ribose) immunostaining was observed in the sciatic nerve of diabetic rats, but not in other groups. Final sciatic motor nerve conduction velocity and digital sensory nerve conduction velocity were reduced by 24% and 22% respectively in diabetic rats compared with controls (p<0.01 for both), and both were 98% corrected by PJ34 (p<0.01 vs diabetic group for both). In contrast, with PJ34 treatment, nerve blood flow showed a modest (17%) increase, and vascular conductance showed a tendency to increase. Free mitochondrial and cytosolic NAD⁺:NADH ratios, assessed from the glutamate and lactate dehydrogenase systems, phosphocreatine concentrations, and phosphocreatine:creatine ratios were decreased in diabetic rats and essentially normalised by PJ34. In both untreated and PJ34-treated diabetic rats, nerve glucose, sorbitol and fructose were increased to a similar extent. PJ34 did not affect any variables in control rats.

Conclusions/interpretation.

Short-term poly(ADP-ribose) polymerase inhibitor treatment reverses functional and metabolic abnormalities of early diabetic neuropathy. Complete normalisation of nerve blood flow is not required for correction of motor or sensory nerve conduction velocities, provided that a therapeutic agent can restore nerve energy state via direct action on Schwann cells.

Virag L, Szabo C (2002) The therapeutic potential of poly (ADP-Ribose) polymerase inhibitors. Pharmacol Rev 54:375–429CrossRefPubMed

Suarez-Pinzon Wl, Mabley JG, Power R, Szabo C, Rabinovitch A (2003) Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes 52:1683–1688PubMed

Garcia Soriano F, Virag L, Jagtap P et al. (2001) Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nature Med 7:108–113CrossRefPubMed

Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C (2002) The role of poly (ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51:514–521PubMed

Obrosova IG, Li F, Abatan OI et al. (2004) Role for poly (ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53:711–720PubMed

Szabo C, Zanchi A, Komjati K et al. (2002) Poly (ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680–2686CrossRefPubMed

Du X, Matsumura T, Edelstein D et al. (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049–1057CrossRefPubMed

Soldatenkov VA, Chasovskikh S, Potaman VN, Trofimova I, Smulson ME, Dritschilo A (2002) Transcriptional repression by binding of poly (ADP-ribose) polymerase to promoter sequences. J Biol Chem 277:665–670CrossRefPubMed

Ha HC, Hester LD, Snyder SH (2002) Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci USA 99:3270–3275CrossRefPubMed

10.

Minchenko AG, Stevens MJ, White L et al. (2003) Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly (ADP-ribose) polymerase activation. FASEB J 17:1514–1516PubMed

11.

Stevens EJ, Tomlinson DR (1995) Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Br J Pharmacol 115:373–379PubMed

12.

Freshwater JD, Svensson CI, Malmberg AB, Calcutt NA (2002) Elevated spinal cyclo-oxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 51:2249–2255PubMed

13.

Pop-Busui R, Marinescu V, Van Huysen C et al. (2002) Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 51:2619–2628PubMed

14.

Vinik AI (1999) Diabetic neuropathy: pathogenesis and therapy. Am J Med 107:17S–26SCrossRefPubMed

15.

Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C (2001) Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 89:684–691PubMed

16.

Zheng L, Peachey N, Szabo C, Kern T (2003) PARP inhibitor corrects diabetes-induced alterations in retinal function and leukostasis. Diabetes 52 [Suppl 1]:A205 (Abstract)

17.

Obrosova IG, Van Huysen C, Fathallah L, Cao X, Stevens MJ, Greene DA (2000) Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 14:1548–1558CrossRefPubMed

18.

Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ (2002) An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16:123–125PubMed

19.

Obrosova IG, Fathallah L, Lang HJ, Greene DA (1999) Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia 42:1187–1194CrossRefPubMed

20.

Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA (2000) Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006–1105PubMed

21.

Tuck RR, Schmelzer JD, Low PA (1984) Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107:935–950PubMed

22.

Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC (1999) Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 42:1120–1130CrossRefPubMed

23.

Cameron NE, Tuck Z, McCabe L, Cotter MA (2001) Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 44:1161–1169CrossRefPubMed

24.

Agthong S, Tomlinson DR (2002) Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy. Ann NY Acad Sci 973:359–362PubMed

25.

Cheng C, Zochodne DW (2003) Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 52:2363–2371PubMed

26.

Obrosova IG, Fathallah L, Stevens MJ (2001) Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol 172:211–219CrossRefPubMed

27.

Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA (2001) Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50:1927–1937

28.

Coppey LJ, Gellett JS, Davidson EP, Yorek MA (2003) Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 37:33–40CrossRefPubMed

29.

Hoeldtke RD, Bryner KD, McNeill DR et al. (2002) Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes 51:2817–2825PubMed

30.

Szabo C, Mabley JG, Moeller SM et al. (2002) Part I: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8:571–580PubMed

31.

Pacher P, Liaudet L, Bai P et al. (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896–904CrossRefPubMed

32.

Obrosova I, Seigel G, Frank R et al. (2003) Early diabetes-induced changes in the retina: comparison of STZ-induced models in rat and mouse. Diabetes 52 [Suppl 1]:A202 (Abstract)

33.

Cameron NE, Gibson TM, Cotter MA (2003) Effects of poly(ADP-ribose) polymerase inhibition on large and small nerve fibre function in experimental diabetes. Diabetologia 46 [Suppl 2]:A315 (Abstract)

34.

Obrosova I, Minchenko A, Kennedy A, Szabo C, Frank R, Stevens M (2002) Poly(ADP-ribose) synthetase inhibitors counteract diabetes- and hypoxia-induced retinal VEGF formation. Ophthalm Res 34 [Suppl 1]:128 (Abstract)

35.

Cooper ME (2001) Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44:1957–1972

36.

Low PA, Nickander KK, Tritschler HJ (1997) The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46 [Suppl 2]:S38–42

37.

Song Z, Fu DTW, Chan YS, Leung S, Chung SSM, Chung SK (2003) Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 23:638–647CrossRefPubMed

38.

Mizisin AP, Steinhardt RC, O’Brien JS, Calcutt NA (2001) TX14(A), a prosaposin-derived peptide, reverses established nerve disorders in streptozotocin-diabetic rats and prevents them in galactose-fed rats. J Neuropathol Exp Neurol 60:953–960PubMed

39.

Calcutt NA, Allendoerfer KL, Mizisin AP et al. (2003) Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy. J Clin Invest 111:507–514CrossRefPubMed

40.

Huang TJ, Price SA, Chilton L et al. (2003) Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 52:2129–2136PubMed

41.

Hounsom L, Corder R, Patel J, Tomlinson DR (2001) Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. Diabetologia 44:424–428CrossRefPubMed

42.

Simbulan-Rosenthal CM, Rosenthal DS, Ding R et al. (1998) Prolongation of the p53 response to DNA strand breaks in cells depleted of PARP by antisense RNA expression. Biochem Biophys Res Commun 253:864–868CrossRefPubMed

43.

Ullrich O, Diestel A, Eyupoglu IY (2001) Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 3:1035–1042CrossRefPubMed

44.

Nishikawa T, Edelstein D, Du XL et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–790PubMed

45.

Obrosova IG, Minchenko AG, Vasupuram R et al. (2003) Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52:864–871PubMed

46.

El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB (2003) High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44:3135–3143CrossRefPubMed

47.

Lee AY, Chung SS (1999) Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13:23–30PubMed

48.

Chung SS, Ho EC, Lam KS, Chung SK (2003) Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 14 [Suppl 3]:S233–236

Titel: Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy
verfasst von: F. Li
C. Szabó
P. Pacher
G. J. Southan
O. I. Abatan
T. Charniauskaya
M. J. Stevens
I. G. Obrosova
Publikationsdatum: 01.04.2004
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 4/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-004-1356-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy

Abstract

Aims/hypothesis.

Methods.

Results.

Conclusions/interpretation.

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Aims/hypothesis.

Methods.

Results.

Conclusions/interpretation.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2004

Transcriptional networks controlling pancreatic development and beta cell function

Brain energy metabolism during hypoglycaemia in healthy and Type 1 diabetic subjects

Thank you Vienna—over to you, Bristol

The effect of exercise on regional adipose tissue and splanchnic lipid metabolism in overweight Type 2 diabetic subjects

Seasonality in clinical onset of Type 1 diabetes in Belgian patients above the age of 10 is restricted to HLA-DQ2/DQ8-negative males, which explains the male to female excess in incidence

Vascular endothelial cadherin and β-catenin in human fetoplacental vessels of pregnancies complicated by Type 1 diabetes: associations with angiogenesis and perturbed barrier function

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin